← Leaderboards
Harris A Gelbard
Children'S Memorial Hospital (Chicago)
$27,114,187
Attributed
$30,433,869
Total exposure
24
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$49,813,210 · 25
By mechanism
P01$33,656,711 · 15
R01$9,012,631 · 3
RF1$3,624,866 · 1
R44$1,761,170 · 2
R21$1,757,832 · 4
Top collaborators
- Niccolo Terrando4 shared
- Val S. Goodfellow3 shared
- Stephen Dewhurst2 shared
- Todd D Krauss1 shared
Most similar at Children'S Memorial Hospital (Chicago)
Same institution · by research overlap
- Howard Eliot Gendelman$44,946,535
Others in their field
Top investigators on “Hiv-1”
- Barton F Haynes · Duke University$476,288,740
- Lawrence Corey · Fred Hutchinson Cancer Center$445,419,385
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$294,186,693
- Constance Ann Benson · University Of California, San Diego$272,046,180
- Peter B. Gilbert · Fred Hutchinson Cancer Center$173,010,936
- Dan H. Barouch · Fred Hutchinson Cancer Center$166,542,502
Research focus
Hiv-1In VitroCellsPreventNeuronsBaseAids NeuropathyIn VivoBrainMicrogliaResearch StudyNeuroinflammationAffectImmuneNeurologicInfectionSynapsesLeadInhibitor/AntagonistMacrophagePhosphotransferasesMonocyteNeurotoxinsResponse
Grant awards (106)
Immunovascular interactions in postoperative delirium superimposed on dementia (DSD).$1,380,185
RF1 · FY2025 · AG
Immunovascular interactions in postoperative delirium superimposed on dementia (DSD).$2,244,681
RF1 · FY2022 · AG
Nanocrystal Quantum Dot Biomimetics of SARS-CoV-2 to Interrogate Neutrophil-Mediated Neuroinflammation at the Blood-Brain Barrier$423,500
R21 · FY2022 · NS · contact PI
Immunoprofiling postoperative delirium during aging and neurodegeneration$198,489
R21 · FY2022 · AG · contact PI
Immunoprofiling postoperative delirium during aging and neurodegeneration$239,843
R21 · FY2021 · AG · contact PI
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1$625,121
R01 · FY2018 · MH · contact PI
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1$630,862
R01 · FY2017 · MH · contact PI
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1$636,438
R01 · FY2016 · MH · contact PI
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1$641,849
R01 · FY2015 · MH · contact PI
MLKi Therapy for Cognitive Impairment in Multiple Sclerosis$586,679
R44 · FY2015 · NS
Novel Adjunctive Therapies for NeuroAIDS$1,344,864
P01 · FY2014 · MH · contact PI
Novel Kinase and Nanoformulated Protease Inhibitors for Eradication of CNS HIV-1$673,852
R01 · FY2014 · MH · contact PI
Inhibition of HIV-Induced Synaptodentritic Damage$607,680
R44 · FY2014 · MH
Project 1$438,171
P01 · FY2014 · MH · contact PI
Project 3$381,633
P01 · FY2014 · MH · contact PI
Project 2$362,376
P01 · FY2014 · MH · contact PI
Platelet Activating Factor, Synaptic Failure & NeuroAIDS$362,093
R01 · FY2014 · MH · contact PI
Core A$162,684
P01 · FY2014 · MH · contact PI
Novel Adjunctive Therapies for NeuroAIDS$1,291,068
P01 · FY2013 · MH · contact PI
Inhibition of HIV-Induced Synaptodentritic Damage$566,811
R44 · FY2013 · MH
Project 1$418,391
P01 · FY2013 · MH · contact PI
Project 3$370,334
P01 · FY2013 · MH · contact PI
Platelet Activating Factor, Synaptic Failure & NeuroAIDS$347,609
R01 · FY2013 · MH · contact PI
Project 2$345,209
P01 · FY2013 · MH · contact PI
Core A$157,134
P01 · FY2013 · MH · contact PI
Novel Adjunctive Therapies for NeuroAIDS$1,344,864
P01 · FY2012 · MH · contact PI
Project 1$433,234
P01 · FY2012 · MH · contact PI
Project 3$391,991
P01 · FY2012 · MH · contact PI
Platelet Activating Factor, Synaptic Failure & NeuroAIDS$362,093
R01 · FY2012 · MH · contact PI
Project 2$355,034
P01 · FY2012 · MH · contact PI
Core A$164,605
P01 · FY2012 · MH · contact PI
Novel Adjunctive Therapies for NeuroAIDS$1,290,412
P01 · FY2011 · MH · contact PI
Project 1$444,926
P01 · FY2011 · MH · contact PI
Project 2$363,396
P01 · FY2011 · MH · contact PI
Platelet Activating Factor, Synaptic Failure & NeuroAIDS$362,093
R01 · FY2011 · MH · contact PI
Project 3$345,993
P01 · FY2011 · MH · contact PI
Core A$170,902
P01 · FY2011 · MH · contact PI
Novel Adjunctive Therapies for NeuroAIDS$34,805
P01 · FY2011 · MH · contact PI
Novel Adjunctive Therapies for NeuroAIDS$1,199,772
P01 · FY2010 · MH · contact PI
Project 1$406,204
P01 · FY2010 · MH · contact PI
Platelet Activating Factor, Synaptic Failure & NeuroAIDS$365,750
R01 · FY2010 · MH · contact PI
Project 3$331,958
P01 · FY2010 · MH · contact PI
Project 2$304,467
P01 · FY2010 · MH · contact PI
Core A$157,131
P01 · FY2010 · MH · contact PI
Novel Adjunctive Therapies for NeuroAIDS$1,721,662
P01 · FY2009 · MH · contact PI
Targeted Neuro Protection of HIV-1 Associated Neurologic Disease$458,372
P01 · FY2009 · MH · contact PI
Platelet Activating Factor, Synaptic Failure & NeuroAIDS$369,790
R01 · FY2009 · MH · contact PI
Core--Biostatistics and Data Management$342,059
P01 · FY2009 · MH · contact PI
Novel HIV Therapies$234,267
P01 · FY2009 · MH · contact PI
Core--Cell and Molecular Core Facility$217,058
P01 · FY2009 · MH · contact PI
Endogenous mechanisms of neuroprotection$210,663
P01 · FY2009 · MH · contact PI
The Axon-Oligodendrocyte Precursor Synapse in NeuroAIDS$192,500
R21 · FY2009 · MH · contact PI
Administrative Core$140,912
P01 · FY2009 · MH · contact PI
Core--Drug Design for the Molecular Target MLK-3$118,331
P01 · FY2009 · MH · contact PI
Novel Adjunctive Therapies for NeuroAIDS$1,675,152
P01 · FY2008 · MH · contact PI
Platelet Activating Factor, Synaptic Failure & NeuroAIDS$531,527
R01 · FY2008 · MH · contact PI
Core--Biostatistics and Data Management$311,470
P01 · FY2008 · MH · contact PI
Targeted Neuro Protection of HIV-1 Associated Neurologic Disease$309,778
P01 · FY2008 · MH · contact PI
Core--Cell and Molecular Core Facility$292,948
P01 · FY2008 · MH · contact PI
The Axon-Oligodendrocyte Precursor Synapse in NeuroAIDS$231,000
R21 · FY2008 · MH · contact PI
Photoconductive stimulation of synapses and HIV neurotoxins$215,854
R01 · FY2008 · MH · contact PI
Novel HIV Therapies$209,338
P01 · FY2008 · MH · contact PI
Endogenous mechanisms of neuroprotection$181,556
P01 · FY2008 · MH · contact PI
Core--Drug Design for the Molecular Target MLK-3$104,928
P01 · FY2008 · MH · contact PI
Novel Adjunctive Therapies for NeuroAIDS$1,669,433
P01 · FY2007 · MH · contact PI
Core--Drug Design for the Molecular Target MLK-3$484,353
P01 · FY2007 · MH · contact PI
Platelet Activating Factor, Synaptic Failure & NeuroAIDS$369,790
R01 · FY2007 · MH · contact PI
Targeted Neuro Protection of HIV-1 Associated Neurologic Disease$363,899
P01 · FY2007 · MH · contact PI
Influence of Glia on Neuronal Function in HIV Infection In Vitro$221,621
P01 · FY2007 · NS · contact PI
Photoconductive stimulation of synapses and HIV neurotoxins$215,854
R01 · FY2007 · MH · contact PI
Novel HIV Therapies$204,722
P01 · FY2007 · MH · contact PI
Endogenous mechanisms of neuroprotection$192,210
P01 · FY2007 · MH · contact PI
Platelet Activating Factor, Synaptic Failure & NeuroAIDS$160,177
R01 · FY2007 · MH · contact PI
Core--Cell and Molecular Core Facility$147,344
P01 · FY2007 · MH · contact PI
Core--Biostatistics and Data Management$59,193
P01 · FY2007 · MH · contact PI
Novel Adjunctive Therapies for NeuroAIDS$1,640,899
P01 · FY2006 · MH · contact PI
Core--Drug Design for the Molecular Target MLK-3$527,407
P01 · FY2006 · MH · contact PI
Platelet Activating Factor, Synaptic Failure & NeuroAIDS$342,752
R01 · FY2006 · MH · contact PI
Targeted Neuro Protection of HIV-1 Associated Neurologic$247,396
P01 · FY2006 · MH · contact PI
Influence of Glia on Neuronal Function in HIV Infection In Vitro$225,083
P01 · FY2006 · NS · contact PI
Photoconductive stimulation of synapses and HIV neurotoxins$214,408
R01 · FY2006 · MH · contact PI
Novel HIV Therapies$146,833
P01 · FY2006 · MH · contact PI
Endogenous mechanisms of neuroprotection$123,200
P01 · FY2006 · MH · contact PI
Core--Cell and Molecular Core Facility$92,400
P01 · FY2006 · MH · contact PI
Core--Biostatistics and Data Management$42,555
P01 · FY2006 · MH · contact PI
Targeted Neuroprotection for HIV-1 Associated Dementia$363,118
P01 · FY2005 · MH
Platelet Activating Factor, Synaptic Failure &NeuroAIDS$351,000
R01 · FY2005 · MH
In Vitro Cell Models of NeuroAIDS$236,250
R21 · FY2005 · MH
Influence of Glia on Neuronal Function in HIV Infection In Vitro$218,565
P01 · FY2005 · NS
Targeted Neuroprotection for HIV-1 Associated Dementia$1,523,482
P01 · FY2004 · MH
In Vitro Cell Models of NeuroAIDS$236,250
R21 · FY2004 · MH
Influence of Glia on Neuronal Function in HIV Infection In Vitro$212,497
P01 · FY2004 · NS
Targeted Neuroprotection for HIV-1 Associated Dementia$1,496,456
P01 · FY2003 · MH
ROLE OF PAF IN HIV-1 NEUROPATHOGENESIS$279,125
R01 · FY2003 · MH
Influence of Glia on Neuronal Function in HIV Infection In Vitro$214,874
P01 · FY2003 · NS
Targeted Neuroprotection for HIV-1 Associated Dementia$77,450
P01 · FY2003 · MH
Targeted Neuroprotection for HIV-1 Associated Dementia$1,408,926
P01 · FY2002 · MH
Targeted Neuroprotection for HIV-1 Associated Dementia$657,515
P01 · FY2002 · MH
ROLE OF PAF IN HIV-1 NEUROPATHOGENESIS$279,125
R01 · FY2002 · MH
HIV 1 and CNS inflammation: prelude to Parkinsonism$266,631
P01 · FY2002 · MH
HIV 1 and CNS inflammation: prelude to Parkinsonism$266,631
P01 · FY2002 · MH
Targeted Neuroprotection for HIV-1 Associated Dementia$639,463
P01 · FY2001 · MH
ROLE OF PAF IN HIV-1 NEUROPATHOGENESIS$325,380
R01 · FY2001 · MH
HIV 1 and CNS inflammation: prelude to Parkinsonism$0
P01 · FY2001 · MH
STRATEGIES TO PREVENT OXIDATIVE STRESS IN CNS AIDS$382,503
P01 · FY2000 · MH
ROLE OF PAF IN HIV-1 NEUROPATHOGENESIS$350,089
R01 · FY2000 · MH